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The American Red Cross Blood Services (ARCBS),
Southern Region, located in Atlanta, Georgia, currently
serves 128 hospitals, primarily in the state of Georgia,
with a service area of 60,000 square miles. The region
distributed approximately 350,000 units of RBCs to its
customers in 2005. Georgia has a population of 8.2
million, with 4.5 million residing in the metropolitan
Atlanta area. Of the four major counties encompassing
this metro area, African Americans make up the
majority of the population in two of these (DeKalb and
Fulton Counties). In metropolitan Atlanta and
throughout Georgia, there are many patients, mostly
African Americans, with sickle cell disease (SCD), who
are in need of RBC transfusions.
Since January 1993, the ARCBS Southern Region
has offered a phenotype-matching transfusion program
for patients with SCD called Partners for Life (PFL). The
physicians and staff at the ARCBS Southern Region
Immunohematology Reference Laboratory (IRL) have
worked closely with the faculty of the Departments of
Adult and Pediatric Hematology and Oncology at the
Emory University School of Medicine as well as at the
Morehouse School of Medicine to develop and further
refine the PFL program. Most of the patients with SCD
enrolled in the PFL program are treated by these same
faculty physicians at the Georgia Comprehensive Sickle
Cell Center, consisting of three major children’s
hospitals in Atlanta: Children’s Healthcare of Atlanta at
Egleston Hospital, Children’s Healthcare of Atlanta at
Scottish Rite Hospital, and the Hughes Spalding
Hospital of the Grady Health System.
In February 2006, Children’s Healthcare of Atlanta
also assumed responsibility for the management of
services at Hughes Spalding Hospital. Today, Children’s
Healthcare of Atlanta is the second largest pediatric
healthcare system in the United States. The Children’s
Healthcare of Atlanta system comprises 430 licensed
beds, 63 of which are dedicated to hematology and
oncology. Each year, Children’s Healthcare of Atlanta
manages approximately 450,000 patient visits, 21,400
hospital admissions, 33,800 surgical procedures,
211,300 emergency department visits, and 8900
specialty clinic visits.
The American Family Life Assurance Company of
Columbus (AFLAC) Cancer Center and Blood Disorders
Service of Children’s Healthcare of Atlanta treats
approximately 1000 pediatric patients per year who
have a diagnosis of SCD. Approximately 300 of the
Children’s Healthcare of Atlanta patients with SCD are
enrolled in the PFL program, and of these, nearly 175
are chronically transfused,using the simple transfusion,
phenotype-matching protocol of the PFL program.
Many of these pediatric patients also require one or
more acute RBC exchange procedures each year,due to
various complications of SCD.
The PFL phenotype-matching protocol has been
essentially identical since its inception in 1993.
Patients with SCD are extensively phenotyped by the
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ARCBS Southern Region IRL upon entry into the PFL
program, before their first transfusion. Patients are
separated into two categories: Category I patients have
no history of prior antibody formation; Category II
patients have already made one or more antibodies
when they enter the PFL program.
Category I patients receive RBCs that are
phenotypically matched for C, E, c, e, and K. Category
II patients receive RBCs that are phenotypically
matched for C, E, c, e, K, Fya, Jka, and Jkb, as well as for
any other RBC antigens to which the patients have
already made antibodies.
All PFL patients receiving simple transfusions are
provided with RBCs that are HbS negative, leukocyte-
reduced, and (if at all possible) less than 14 days old.
For patients with SCD undergoing acute RBC
exchange, every attempt is made to procure the
appropriate phenotypically matched RBCs that are less
than 10 days old.
RBCs that are CMV negative or irradiated are not
routinely provided to PFL patients. On rare occasions,
such as for transfusion of those patients preparing for
or undergoing marrow or stem cell transplants for SCD,
irradiated or CMV-negative components may be
requested and provided.
From 1993 until 2000, the PFL program was a
limited-donor, phenotype-matching program, with each
PFL patient being assigned between eight and ten
partially phenotypically matched blood donors. PFL
blood donors would commit to donating RBCs for their
“partner” patients with SCD, according to the chronic
simple transfusion schedule set for each of the
patients.
Although the PFL program was successful in
reducing the alloimmunization rate in this group of
children during that 7-year period to less than 7
percent, down from the previous rate of more than 20
percent, only 6 percent of PFL patients received all of
their RBC transfusions exclusively from their PFL
donors. The vast majority of PFL patients received a
combination of RBCs from their PFL donors and RBCs
from phenotypically matched units (using PFL
Category protocols) from the general blood donor
pool. The reasons for this lack of adherence to
protocol are many, and have to do with the
complicated logistics of matching a specific donor’s
blood unit with a specific patient’s transfusion
schedule.
Another component of the difficulty in having only
PFL units go to each PFL patient is caused when PFL
patients present to nonparticipating hospitals in
(typically) emergent situations. Although the patients’
guardians have always been given PFL cards stating
their children’s RBC phenotypes and any RBC
antibodies already made, many of these children
received RBC units at nonparticipating hospitals that
were not phenotypically matched, contributing to the
7 percent alloimmunization rate observed in PFL
patients.
Given the complicated logistics and higher costs
associated with the special recruitment of partner
donors, the constant and often confusing communi-
cation with hospitals about each PFL patient’s
transfusion schedule, the difficulties in scheduling
partner donors’ collections to meet each separate
patient’s transfusion schedule, the “no-show” rate for
donors and patients, and the time-sensitive shipping of
the PFL donor units, the ARCBS Southern Region
converted, in 2000, to the use of phenotypically
matched RBCs from the general donor pool for its PFL
program patients. This change instantly created a larger
pool of donors from which to screen units for rapid
provision to SCD patients.
This change also made the logistics of the PFL
program more efficient, especially as regards effective
communication between the blood center and its
partner hospitals. Each week, the hospitals now
electronically send the ARCBS Southern Region IRL a
list of all PFL patients who are scheduled for chronic
transfusion during the following week. The IRL then
tests for and determines the appropriate RBCs needed
for each patient scheduled for transfusion, and ships
the freshest units possible prior to the anticipated date
of transfusion.
The alloimmunization rate in the PFL program is
currently around 5 percent. It is believed that the rate
has not dropped closer to 0 because many PFL patients
continue to present to nonparticipating hospitals for
emergency transfusions and often receive non-
phenotypically matched RBC units at those hospitals.
There is currently no specific telerecruitment
strategy for recruiting blood donors into the PFL
program. The ARCBS Southern Region does have an
active African American blood donor recruitment
campaign;the donor recruiters are knowledgeable about
SCD and the importance of African American donations
to the care and well-being of patients with SCD.
A unique and special contribution to the success of
the PFL program in building an appropriate blood
inventory has been the region’s nationally recognized
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Minority Donor Recruitment Advisory Board,
comprising African American leaders in government,
business, nonprofit, religious, and other organizations
throughout the State of Georgia. These board members
have truly embraced the cause of increasing blood
donations by African Americans; they emphasize the
importance of blood donation daily within their places
of business, their communities, their churches, and in
other settings as well. They personally host or support
blood drives at churches, businesses, and other organi-
zations comprising primarily African Americans,
including the Historically Black Colleges and
Universities of the Atlanta University Complex. These
college campuses have strongly supported the ARCBS
Southern Region in holding successful blood drives on
several occasions each year.
The success of this recruitment campaign in raising
awareness about the importance of blood transfusion
within the large African American population in
Georgia has greatly contributed to the region’s ability
to maintain the appropriate inventory with which to
supply partially phenotypically matched RBCs to all
patients with SCD in the region’s service area.
A special communication process occurs daily
among the collections staff, the donor information
databases, the data entry employees, the manufacturing
laboratory personnel, and the IRL staff within the
region, to identify appropriate units for testing and
phenotype matching. Approximately 13 percent of all
donors in the ARCBS Southern Region self-identify as
African American on their blood donation records.
RBCs from these donors are initially screened by the IRL
for C and E, using automated RBC typing equipment.
When additional serologic testing identifies a donor
with the correct phenotype for a PFL patient, a “flag” is
entered by IRL staff into the computer system, so that
any future donations from that donor will be sent
directly to the IRL after RBC processing and testing.
After initial identification, donors are informed of
their special RBC phenotype status via a letter,
explaining the importance of their donations to
patients with SCD; a special PFL wallet-size card is
included in the letter. This card may be presented by
the donor to collections staff members at blood
collection sites, to further identify these special units
for patients with SCD. Of note, approximately 400 PFL
donors from the former limited-donor pool program
remain actively involved in the “new”PFL program, and
they donate at regular intervals to provide RBCs for any
PFL (or SCD) patient in need.
Approximately 5500 phenotypically matched RBCs
were distributed last year for acute and chronic
transfusions from the ARCBS Southern Region to
patients with SCD who were actively enrolled in the
PFL program. It is estimated that at least 4000 blood
donors with the correct phenotypes are needed each
year to support the ARCBS Southern Region’s PFL
phenotype-matching program. This estimate includes
many variables, such as the predicted number of units
to be distributed for PFL patients during the year, the
rate of unsuccessful donations (as a result of “quantity
not sufficient,” donor deferrals, etc.), the RBC discard
and donor “no-show” rates, and the number of times
each year each donor gives blood. Of note, the majority
of PFL donors donate more than once per year.
It is important to note that many phenotypically
matched RBCs are supplied by the ARCBS Southern
Region to patients with SCD who are not officially
enrolled in the PFL program; most adults at the
academic center’s hospitals (as well as at other large
hospitals throughout the state) who require trans-
fusion for SCD receive phenotypically matched units
from the ARCBS Southern Region, most often using the
same phenotype-matching protocol as for PFL. Many of
these adults are on chronic transfusion protocols;many
often require acute RBC exchange transfusion
(erythrocytapheresis) as a result of acute chest
syndrome, cerebrovascular accidents, multisystem
organ failure, and other complications of their disease.
Each year, approximately 12,000 phenotypically
matched RBCs are distributed to meet the transfusion
needs of all adult and pediatric patients treated for SCD
within the 60,000 square-mile service area for which
the ARCBS Southern Region is the primary blood
supplier. Using the same variables as were considered
above (discard rate, no-show rate, etc.), it is roughly
estimated that at least 10,000 blood donors with the
appropriate phenotypes are needed each year to
support the transfusion needs of all patients with SCD
in the State of Georgia.
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